Researcher Announced Cure for Hepatitis C

The use of peginterferon alone, or in combination with ribavirin, points to a cure for hepatitis C, the leading cause of cirrhosis, liver cancer and the need for liver transplant, a Virginia Commonwealth University researcher said today. Mitchell Shiffman, M.D., professor in the VCU School of Medicine, and chief of hepatology and medical director of the Liver Transplant Program at the Virginia Commonwealth University Medical Center, is one of the lead investigators in the study, which was presented at the 38th annual Digestive Disease Week conference in Washington, D.C. VCU was among about 40 sites worldwide studying pegylated interferon alfa-2a, manufactured by Roche Inc. Nearly all -- 99 percent – of patients with hepatitis C who were treated successfully with peginterferon alone, or in combination with ribavirin, had no detectable virus up to seven years later. Researchers say this data validates the use of the word "cure" when describing hepatitis C treatment as successful treatment is defined as having undetectable hepatitis C virus in the blood six months following treatment. "We at VCU are encouraged by this data because it is rare in the treatment of life-threatening viral diseases that we can tell patients they may be cured," Shiffman said. "In hepatitis C today, we are able to help some patients achieve an outcome that effectively enables them to... Whole article: "http://www.physorg.com":[ http://www.physorg.com/news99059944.html]

---

Related articles

Hepatitis C Growth In Liver Cells Slowed By Protein - Biomedical researchers have identified a cellular protein that interferes with hepatitis C virus replication, a finding that ultimately may help scientists develop new drugs to fight the virus (4.5.2007)

Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins - Hepatitis C virus (HCV) and triglyceride-rich very low-density lipoproteins (VLDLs) both are secreted uniquely by hepatocytes and circulate in blood in a complex (6.4.2007)

ViroPharma Announces Presentation Of New HCV-796 In Vitro Data At The 13th International Meeting On Hepatitis C Virus & Related Viruses - ViroPharma Incorporated (Nasdaq: VPHM) today announced the presentation of additional preclinical data on HCV-796, an orally dosed non-nucleoside hepatitis C virus (HCV) polymerase inhibitor being co-developed with Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), at the 13th International Meeting on Hepatitis C Virus & Related Viruses in Cairns, Australia (5.9.2006)

Genetic Test to Give Clues on Treatment of Hepatitis C - Celera Genomics plans to announce today that it has developed a genetic test it says can help predict which patients with hepatitis C will eventually suffer liver scarring and so are in most need of treatment (9.5.2006)